Feedback Share Discussion Threads

[lr2] 11/5/2015 08:43

As you say BB, just a waiting game. I wouldn't be at all surprised if a few more sales of TexRAD don't surface in the meantime.

[blueball] 11/5/2015 08:38

Thanks for that LR2 just a waiting game over the next few weeks.

[lr2] 10/5/2015 20:29

You could be right BB but in the Interim Report, the Chairman said, "The FDA approval application for the Group’s software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015."

It might be a few more weeks yet.

[blueball] 10/5/2015 20:08

Just guessing we will hear about FDA approval.

[113mike] 10/5/2015 18:48

Cool! What news is that then?

[blueball] 10/5/2015 18:34

I'm expecting news this week.

[davydoo] 08/5/2015 15:49

Those two events have made me happy on this day, that is all.

after that lot, its got to be Peckham surely

[lr2] 08/5/2015 15:46

Not sure there's a connection between those two events Davy.

Berlin, Cardiff, Tokyo, Reims, Seoul, Brisbane, Oxford.

Where's next? News soon hopefully.

[davydoo] 08/5/2015 14:42

A Tory election win and Feedback at 1.95p? thank you very much

[blueball] 05/5/2015 16:31

Are we expecting news this month..?

[davydoo] 01/5/2015 11:48

The more mobile imaging there is out there the more need there is for an image management system like Cadran and tools like TexRad used remotely.

The TexRad deals have been exciting, but could it be the (boring?) Cadran part of the business that really delivers in future?

[davydoo] 01/5/2015 08:28

Hardware rather than software, but this deal still interesting...



Imaging, mobile imaging, and even some suggestion I saw that Labour want Cancer detection in GP surgeries all points to a lot of opportunity here.

[davydoo] 01/5/2015 08:25

1.99p? thank you very much

[blueball] 01/5/2015 08:10

£20 mill placing at AVO today should keep them going for a while..

Bit quiet here before the long weekend.

[sja123] 30/4/2015 15:33

"imminenter and imminenter" :-)

[blueball] 30/4/2015 15:26

Expect more contract news imminenter.

[the stigologist] 30/4/2015 14:21

double top on the chart

[the stigologist] 30/4/2015 14:20

placing imminenter

[sja123] 30/4/2015 14:17

Looking at the interims in March this year, they say:

"The FDA approval application for the Group’s software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015"

[sja123] 30/4/2015 14:07

Although from June 2014, the Peterhouse note provides lots of good information for prospective investors and confirms that regulatory approval is expected "early 2015"....

[blueball] 30/4/2015 08:50

One to tuck away for the next few years still early days.

[sja123] 29/4/2015 23:18

I would suggest that the reason the four contracts are only for twelve months is because they are research contracts and these centres are evaluating the software which is sold as a research tool at the moment...Once regulatory approvals are received in the various geographies and centres are happy that the software improves treatment and outcomes, the product will be sold commercially, by licence and possibly as a pay per scan model, as has been mentioned....Personally, I find it difficult to see why a tool which enhances the ability of clinicians to focus the correct treatment more cost effectively and therefore likely produce better outcomes for patients, whilst utilising scans which are already routinely done, would not be widely adopted and ultimately be a normal part of the treatment process in all areas which use medical imaging....This is one to tuck away IMO.....

[lr2] 29/4/2015 22:16

I'm finding it difficult to make sense of the revenue information we currently have.

This year's H1 revenue was stated as £229k but the news releases covering that period only make reference to 3 research sites, 2 hospitals (London & Colchester) and 1 university (Rome). That would imply a revenue stream of £76k per site and as the research appears to have commenced in November 2014 which is also the cut off point for the H1 report then it would appear that substantial income from these 3 sites was paid up front.

Revenue from those 3 sites is unlikely to have been booked monthly as I had previously assumed which could imply that no further income will be forthcoming.

Of the 7 sites (Berlin, Cardiff, Tokyo, Reims, Seoul, Brisbane, Oxford) that have subsequently taken up the software during April, the first 4 definitely have revenue booked over the full 12 month term of each contract. See quote below.

"These recent sales of TexRAD, together with others over the last two months with a combined sales value of over £100,000, are a further indication of the interest in TexRAD as a potentially valuable quantitative tool in cancer research. The revenue associated with these sales will be recognised over the life of the 12 month contracts in accordance with the Company's revenue recognition accounting policy."

Seoul is probably the same but it has not been clearly stated, whilst Oxford and Brisbane are strictly research at present and likely being treated differently.

If Oxford and Brisbane are not paying on a regular monthly basis then any money received from them should come as an up front payment falling into FY 2015 whilst the vast majority of the aforementioned £100k plus from Berlin, Cardiff, Tokyo, Reims, and Seoul will fall into FY2016.

[davydoo] 29/4/2015 21:04

Apologies LR2'ive looked back and it does seem that the 4 contracts announced are all only 12 months, seems more like a payment plan than an ongoing licence, but that's the deal they did. So they have a job next year, win new clients and secure extensions to those signed this year, that's when this gets interesting, how successful was the first year? And will they extend?